Topic: Healthcare Operations

image

Pharmaceutical supply chain analysis-low and middle income countries

Funding Body: Department For International Development Type of Funding: Private Main Researcher: Prashant Yadav Term: 30/11/2007-31/08/2008 Project Description The purpose of this consultancy is to develop an analytic tool/framework for mapping the supply chain that can be used in MeTA countries. The framework will be developed and then tried in 2-3 MeTA countries as part […]

image

Drug Resistance Working Group

Funding Body: The center for global development Main Researcher: Prashant Yadav Term: 01/11/2007-30/09/2008 Project Description The project has three main subjects that should be identified: The role of all the bodies that form part of the supply chain of certain products, paying attention to the markets of medications for tuberculosis and other antibiotics, and focusing […]

image

HIV/AIDS Monitor

Funding Body: The center for global development Main Researcher: Prashant Yadav Term: 01/11/2007-30/09/2008 Project Description The project consists in studying the following objectives: Identifying the risks to which agents involved in the antiretroviral supply chain are subjected to in such a way that they undermine efficient behaviour and make access to said antiretrovirals less than […]

image

Mapping Private Sector Supply Chains for Pharmaceutical Products in Developing Countries

Researcher: Prashant Yadav Term: September 2007 Project Sponsor: UK Department for International Development. Pilot study done in Zambia and Kyrgyzstan Project Description One third of the world’s population lacks access to essential medicines. This situation persists despite increased government and donor financing for health, in part due to fundamental inefficiencies in the pharmaceutical market and across […]

image

Global Subsidy for Antimalarial Drugs Defining Architecture and management and Building a Coalition

Funding Body: Dalberg Global Development Advisors Main Researcher: Prashant Yadav Term: 01/06/2007-31/09/2007 Project Description Artemisinin-combination therapies (ACTs) substantially delay the emergence and spread of artemisinin- resistant strains of falciparum malaria and they should be made available at affordable prices. In 2004, the Institute of Medicine concluded that a global high-level subsidy was the best way […]

image

Global Demand Forecasting for Anti-Malarials

Researcher: Prashant Yadav Term: 2007 Project Sponsor: Roll-Back Malaria Partnership, Geneva http://www.rollbackmalaria.org/ Project Description Every year, over a million people die from malaria–most of them children–and hundreds of millions more suffer from disease and disability. Along with the devastating human toll, the economic costs to many African countries are massive. The malaria burden has increased in […]

image

Mapping and Realigning Incentives in the Global Health Supply Chain (Risk and Incentive study of Global Health Supply Chains)

Researchers: Prashant Yadav, Kirsten Curtis and Neelam Sekhri Dec 2006 Centre for Global Development: Global Health Forecasting Working Group Background Paper http://www.cgdev.org/ Project Description Poor allocation of risks among the constituents of a supply chain results in a misalignment of incentives, leading to over-reactions, unnecessary interventions, second guessing, mistrust, and distorted information – ultimately degrading […]

image

Towards a Medicines Transparency Alliance (MeTA), Mapping the Supply Chain in Zambia

Funding Body: Department For International Development Main Researcher: Prashant Yadav Term: 11/09/2006-15/12/2006 Project Description The project has three main points that should be identified: The role of all the bodies in health product supply chains, focusing on the malaria treatment and antiretroviral drug markets. The capacity of each of the agents to mitigate the risk […]

image

Supply Chain Risk and Incentive Analysis to Counter Drug Resistance

Project Description Emergence of drug resistant is posing a major threat to global disease eradication programmes. This phenomenon is framed within global drug supply chains, which are inherently more risky than domestic supply chains due to the numerous links interconnecting a wide network of firms. The traditional approach to effective supply chain risk mitigation involves […]